Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-finding study of vemircopan in proliferative lupus nephritis or IgA nephropathy
2023-504825-38-00Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 2, randomised, double-blind trial in lupus nephritis (LN) and IgA nephropathy (IgAN) comparing Vemircopan with Placebo (2 arms). Primary endpoint: Percentage change in proteinuria. Started May 2024; status: completed.
02
Drugs
vemircopan
03
Conditions
lupus nephritis (LN)IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2023-504825-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504825-38-00.